The agency approved an investigational new drug application to test PM647 for Alpha-1 Antitrypsin Deficiency.
Live Poll
Do you trust new genetic therapies to effectively treat inherited diseases in the long term?
September 24, 2026
Cullinan Therapeutics Shares Fell After Data DelayThe biotech firm rescheduled critical arthritis results as its stock price faced significant downward pressure.
September 24, 2026
Sarepta Will Present Neuromuscular Research in San AntonioThe company will share seven research posters during a scientific meeting taking place from September 25-27, 2026.
September 24, 2026
Kyverna Therapeutics Reported Clinical Trial ResultsThe company shared long-term data for its cell therapy candidate, miv-cel, in patients with stiff-person syndrome.
September 24, 2026
Merck Reported Positive Trial Results for RemigromigThe pharmaceutical giant announced trial data for a new eye drug while noting potential safety concerns.
September 24, 2026
FDA Approved New Potency Assay for RyoncilThe federal agency has cleared a new testing method to ensure quality for the cell therapy used in children.
September 23, 2026
Gene-Editing Stocks Fell Following AI ReportShares across the gene-editing sector declined after Anthropic's AI model identified a potential new DNA system.
September 23, 2026
Heidi Overton Will Address Senate on FDA StrategyThe FDA nominee will discuss efforts to expedite clinical trials and counter China's biotech industry growth.
September 23, 2026
FDA Granted Breakthrough Status to Glycomine DrugRegulators approved the designation for GLM101 to treat a rare genetic disorder affecting glycosylation.
September 23, 2026
Anthropic AI Discovered New Enzyme SystemThe Claude AI model identified a novel DNA enzyme system while analyzing over a billion protein clusters.
September 23, 2026
Ollin Biosciences Reported Positive JADE Study ResultsThe experimental drug OLN324 showed vision gains and durability in treating macular degeneration during clinical testing.
